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Abstract
Background: Leishmania major and Leishmania infantum are among the main species that are responsible for
cutaneous leishmaniosis (CL) and visceral leishmaniosis (VL), respectively. The leishmanioses represent the
second-largest parasitic killer in the world after malaria. Recently, we succeeded in generating a plasmid DNA
(pCMV-HISA70m2A) and demonstrated that immunized mice were protected against L. major challenge. The
efficacy of the DNA-vaccine was further enhanced by the inclusion of KMP-11 antigen into the antibiotic-free
plasmid pVAX1-asd.
Methods: Here, we describe the use of a HisAK70 DNA-vaccine encoding seven Leishmania genes (H2A, H2B,
H3, H4, A2, KMP11 and HSP70) for vaccination of mice to assess the induction of a resistant phenotype
against VL and CL.
Results: HisAK70 was successful in vaccinated mice, resulting in a high amount of efficient sterile hepatic
granulomas associated with a hepatic parasite burden fully resolved in the VL model; and resulting in 100 %
inhibition of parasite visceralization in the CL model.
Conclusions: The results suggest that immunization with the HisAK70 DNA-vaccine may provide a rapid,
suitable, and efficient vaccination strategy to confer cross-protective immunity against VL and CL.
Keywords: Leishmania infantum, Leishmania major, Cross-protection, Leishmaniosis, Vaccine, DNA, Histones, A2,
Kmp11, Hsp70, Granuloma
Background
The leishmanioses cover a range of vector-borne diseases
caused by infection with various species of intracellular
protozoan parasites of the genus Leishmania [1]. Although
the burden of the leishmanioses and other neglected trop-
ical diseases (NTD) mainly falls on the poorest areas of the
global population [2–4], current studies show that these
NTD are adapting to changing environments and spreading
into new geographical areas worldwide [5, 6]. Specifically,
the leishmanioses have been endemic in southern Europe
for centuries [7]. Nevertheless, the northward spread of
parasites from the Mediterranean region will depend on
whether climate and land cover permit the sand flies
vectors to establish seasonal biting rates that match those
of southern Europe [5, 8, 9]. Recent published data from a
focus of human leishmaniosis have demonstrated that
several isolates are representative of a new human-infective
Leishmania sp. in Ghana [10].
Additionally, Leishmania infantum isolates from an
endemic area in Spain have been able to infect more than
560 of immunocompetent patients and these parasites have
exhibited high virulence in terms of infection index [11].
The most common forms are cutaneous leishmaniosis
(CL), which causes skin sores and social stigmatization, and
visceral leishmaniosis (VL), which affects several internal
organs (spleen, liver and bone marrow) and is potentially
fatal if untreated. The leishmanioses represent the second-
largest parasitic killer in the world after malaria [12]. There
is now an urgent need for an effective vaccine for veterinary
and medical prophylaxis [13]. Leishmania major in the Old
World, and L. infantum (= L. chagasi) in the Mediterranean
region of the Old World and in the Americas [14, 15] are
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among the main species that are responsible for CL and
VL, respectively. Also, canine leishmaniosis is endemic in
the Mediterranean basin, and is a public health problem
which should be tackled [16, 17].
On another note, there is still no vaccine for use in
humans [18], and conventional chemotherapies for the
treatment of CL and VL are usually long, expensive and
inadequate due to toxicity and resistance [19]. Nevertheless,
new approaches from both nanomedicine or inventions
related to the cream formulations are very important,
avoiding the side effects of drugs during the treatment
[20, 21]. Advances in our understanding of Leishmania
pathogenesis and the generation of host protective
immunity in animal models facilitate the development
of this urgently needed vaccine [22, 23]. DNA vaccines
are not only reasonably simple to manage but also
immunogenic and offer a protein similar to the native pro-
tein. Furthermore, the induction of Th1 and CD8+ T cell
immune responses, a common property of DNA vaccines,
is essential to Leishmania infection control [22]. Taken
together, DNA vaccination against Leishmania has been
considered a hopeful technology and the development of
such a preclinical trial-vaccine (LEISHDNAVAX) for use in
humans has been recently tested ex-vivo in human cells
and in rodent models of VL and CL [24, 25]. In addition,
the novel LEISHDNAVAX-DNA vaccine candidate in
combination with a standard antileishmanial drug seems to
improve the treatment of the experimental murine VL [26].
The main area of our research interests are the develop-
ment of suitable protocols both as a prophylactic as well as
a therapeutic vaccine against multiple Leishmania species
using efficient multiantigenic formulations. Recently, the
plasmid pCMV-HISA70m2A was generated and used to
vaccinate mice against L. major infection in our laboratory.
We demonstrated that genetic immunization with pCMV-
HISA70m2A provided protection in mice against both foot-
pad swelling, and visceralization in the model of CL [27]. In
addition, in the present study, the efficiency of the DNA-
vaccine has been further enhanced by the inclusion of
KMP-11 (kinetoplastid membrane protein-11) antigen (Ag)
into the antibiotic-free plasmid pVAX1-asd. We focus on
seven Leishmania Ag (the four core histones, A2, KMP11
and 70 kDa heat shock protein (HSP70)) that have already
been successfully tested as DNA vaccines against CL or VL
[22, 27]. The molecule KMP-11 is found in association with
membrane structures (at the cell surface, flagellar pocket
and intracellular vesicles) [28] in the kinetoplastid protozoa
[29] and is highly conserved (>95 % homology) in all Leish-
mania species. Thus, as a special feature considering pro-
tein localization sites in the parasite, KMP-11 is both an
extracellular and intracellular Ag. Additionally, KMP-11
plays an essential role in the infectivity-virulence (its surface
expression is higher in amastigotes than in promastigotes
and increases during metacyclogenesis) and other biological
features of the parasite [30, 31]. Furthermore, several stud-
ies based on DNA vaccination [32–34], peptide-pulsed
dendritic cells (DC) [35], or synthetic multi-epitope peptide
strategies [36] have shown the efficacy of the immunodomi-
nant Ag KMP-11 against experimental CL and VL. The rest
of the components of the HisAK70 vaccine are exclusively
intracellular Ags. The protective potential of the nucleo-
somal Leishmania histones [37, 38] and H1 [39] have been
described. A2 protein is an amastigote specific virulence
factor that is required for Leishmania parasite survival in a
mammalian host and plays a role in the visceralization dur-
ing VL [40]. Immunization, with the A2 as DNA, offered
protection against the invasion of macrophages and disease
progression in a murine model of VL [40–42]. Finally, the
single HSP70 as DNA failed to confer protection in a mur-
ine model of CL [43], whereas administration of the HSP70
gene from the parasite fused with other Ags in a DNA
vaccine showed high efficacy against VL [44] and CL [27].
In this study by applying lessons learned from the
past, we have enhanced a DNA-vaccine to provide
cross-protection against CL and VL. For this purpose,
we have cloned the full-length coding sequences of
seven Leishmania genes, as we mentioned before, into
the mammalian expression vector pVAX1 that
expresses the resulting polyprotein, called HisAK70, in
mammalian cells. The plasmid pVAX1-HisAK70 was
used to vaccinate BALB/c mice against both L. major
and L. infantum challenges.
Methods
Ethics statement
The animal research described in this manuscript complied
with Spanish (Ley 32/2007) and European Union legislation
(2010/63/UE). The protocols used were approved by the
Animal Care Committee of Complutense University of
Madrid (reference number 02/11/10). All procedures and
euthanasia were performed under C02 anesthesia, and all
efforts were made to minimize suffering.
Vaccine preparation process
In this study, we followed our previous method [27] to
retrieve the sequences of different Leishmania genes
from the annotated collections of all publicly available
DNA sequences (GeneDB and GenBank databases):
H2A (Lin J21.V3.1160), H2B (Lin.J09.V3.1410), H3 (Lin
J10.V3.0920), H4 (Lin J31.V3.3320), A2 (GenBank S696
93), KMP11 (GenBank XM_001468996.1), and HSP70
(GenBank CAA69282.1). Subsequently, GeneOptimizer®
software generated the optimized sequences [45] that
were synthesized chemically (GeneArt) as a single cod-
ing region of 4416 bp (HisAK70). This sequence en-
codes the carboxy-terminal Epitope tag (E-Tag) fusion
polyprotein (from N- to C-terminus, H2A-H2B-H3-H4-
A2-KMP11-HSP70-E-Tag) of 1472 amino acid residues.
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E-Tag is a short peptide sequence (13 amino acids) use-
ful for the labeling and detection of proteins using west-
ern blotting technique. This expression cassette was
cloned into the eukaryotic expression plasmid pVAX1
(Invitrogen) to obtain the recombinant plasmid
pVAX1::HisAK70.
In order to avoid the potential biosafety and clinical
hazards derived by using antibiotic resistance genes in
DNA vaccines, in this work we followed a previously
described system based on the use of the asd (aspartate-
semialdehyde dehydrogenase) gene as a selection marker
to replace the antibiotic resistance markers [46, 47].
Thus, the resistance gene for kanamycin in pVAX1::Hi-
sAK70 was replaced by the asd gene. We obtained
antibiotic-free plasmids pVAX1::HisAK70-asd and
pVAX1-asd as follows (see details in Fig. 1). The asd
gene (GenBank AE017220) from the genome sequence
of Salmonella enterica serovar Choleraesuis strain SC-
B67 was amplified by PCR and excised (KpnI/PacI). Sub-
sequently, the fragment was purified and then ligated
into ΔkanrpVAX1::HisAK70 (previously digested with
these enzymes). pVAX1-asd was generated following a
similar method but using the corresponding template
for inverse PCR (pVAX1). Ligation mixtures were trans-
formed into electrocompetent Δasd E. coli cells (mutant
strain χ6212 which lacks the asd gene) that was kindly
provided by Kenneth Roland and Roy Curtiss III at the
Biodesign Institute (Arizona State University, USA) [48].
The recombinants were identified on LB agar plates, and
the E. coli colonies were screened by PCR and sequence
analysis.
The expression plasmid pVAX1::HisAK70-asd and empty
vector (pVAX1-asd) were purified using the EndoFree
plasmid Giga kit (Qiagen, Hilden, Germany) according to
the manufacturer’s recommendations. The endotoxin-free
DNA plasmids were resuspended in sterile saline solution
and were stored at −20 °C until the day of vaccination.
Transfection of plasmid constructs and Western blotting
The expression of HisAK70 was detected in mamma-
lian cells by transiently transfecting pVAX1::HisAK70-
asd into Chinese Hamster Ovary (CHO-K1) cells using
Lipofectamine LTX and PLUS Reagent (Invitrogen-life-
Technologies) according to the protocol (Protocol Pub.
No. MAN0007822 Rev.1.0) provided by the manufac-
turer. CHO-K1 cells were seeded (into 24-well plates at
a density of 1.5 × 105 cells per well) in F12 K Medium
(Kaighn’s Modification of Ham’s F12 Medium, Gibco)
with 10 % fetal calf serum (FCS) and 2 mM L-glutam-
ine at 37 °C in 5 % CO2. The CHO-K1 cell cultures
A B
C D
Fig. 1 Schematic diagram of the construction of pVAX::HISAK70-asd and pVAX-asd. The kanamycin resistance gene in the eukaryotic expression
vectors was replaced by the asd gene. a To generate pVAX::HISAK70 without kanamycin resistance cassette (Kanr), inverse PCR with primers
noKanPacI-1R 5’-CTTGTTTAATTAA GCGAAACGATCCTCATCCTGTC-3’ (PacI site underlined) and noKanKpnI-1D 5’-GACGAGGGTACCATTATTAACGCT-
TACAATTTC-3’ (KpnI site underlined) were employed for outward amplification. The asd gene starting at bp 170 and ending at bp 1345 was PCR
amplified from bacterial chromosomal with primers asdKpnI-1D 5’ CTGCAAGGTACCCTACGCCAACTGGCGCAGCAT-3’ (KpnI site underlined) and the
asdPacI-1R 5’-TTGGCTGTTAATTAAATGGTGAAGGATGCGCCACAG-3’ (PacI site underlined) creating an amplicon with PacI and KpnI sites on its ends.
b To generate pVAX1 without Kanr, inverse PCR with primers noKanPacI-1R and noKanKpnI-1D were employed for outward amplification. c–d The
PCR products of asd, ΔkanrpVAX1::HISAK70 and ΔkanrpVAX1 were each double digested with PacI and KpnI, gel isolated, ligated, and transformed.
Thus, pVAX1::HisAK70-asd and pVAX1-asd without resistance gene were obtained
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were maintained at 90 % confluence and subsequently,
they were transfected and incubated for 48 h at 37 °C
with 5 % CO2. Then, the cells were harvested and lysed
by the addition of 40 μL per well of Laemmli’s buffer
(Bio-Rad) containing beta-mercaptoethanol. Lysates
(15 μL) were resolved by SDS-PAGE (sodium dodecyl
sulfate polyacrylamide gel electrophoresis). Protein
bands were electrophoretically transferred to a polyvi-
nylidene difluoride (PVDF) membrane (GE Healthcare),
which was blocked for 1 h in TBST blocking buffer
(Tris-Buffered Saline and Tween 20). To detect the Ag
blotted on the membrane, a mouse monoclonal anti-
Leishmania A2 antibody (Abcam ab150344) was added
at an appropriate dilution (1:500) and incubated with
the membrane. E-tag was also detected by monoclonal
HRP/ Anti-E Tag Conjugate (GE Healthcare Life
Sciences) diluted to 1:5000. Because β-tubulin is ubi-
quitously expressed in all eukaryotic cells, it was used
as a loading control for Western blotting assays involv-
ing protein detection. Thus, the membrane was probed
with a β-tubulin loading control monoclonal antibody
(Sigma) at a dilution of 1:5000 for 1 h at room
temperature, washed in TBST, and probed with an
HRP-conjugated anti-mouse IgG secondary antibody
(Sigma) at a dilution of 1:15,000. Detection was
performed using a chemiluminescent substrate (Pierce®
ECL western Blotting). Immunoreactive bands were
detected using the ChemiDoc™ XRS+ System with
Image Lab 5.2 Software (Bio-Rad LifeScience).
Mice, parasites and preparation of soluble Ag
Eight-week-old female BALB/c mice (Harlan Interfauna
Ibérica) were maintained at Complutense University of
Madrid under standard conditions. L. infantum parasites
(M/CAN/ES/96/BCN150 zymodeme MON-1) and L.
major parasites (clone V1: MHOM/IL/80/Friedlin) were
maintained as previously described [49]. Soluble Leish-
mania Ag (SLA) was prepared from stationary cultures
of promastigotes as previously described [50].
Vaccine schedule
Two groups of mice (n = 30) subcutaneously (s.c.) re-
ceived 175 μg of pVAX1::HisAK70-asd (HisAK70) or
pVAX1-asd (empty vector) in 40 μL saline in the right
footpad on days−60,−45 and−30. In parallel, a group of
control mice (n = 15) was inoculated with PBS alone
using the same procedure.
Infection protocols
To evaluate the vaccine efficacy against VL, fifteen mice
of each group were then infected by intravenous injec-
tion of 5 × 105 stationary-phase promastigotes of L.
infantum in 100 μl PBS at day 0. Five mice of each
group were euthanized after 28, 42 and 91 days of
infection, respectively. After sacrifice, the spleens and
livers were removed and subjected to a limiting dilution
assay for a parasite load assessment. To evaluate vaccine
effectiveness against CL, five mice of each group were
infected s.c. in the left footpad with high dose challenge
(5 × 105 metacyclic L. major promastigotes) in a volume of
30 μL at day 0. Infective-stage promastigotes (metacyclics)
were isolated from stationary cultures (5 days old) by nega-
tive selection using peanut agglutinin (Vector Laboratories),
as previously described before [51]. The course of infection
was monitored weekly by measuring footpad swelling with
a caliper. Mice were euthanized by cervical dislocation at
5 weeks post-infection (p.i.) because at this time, the lesions
from control groups were larger than 4 mm in diameter or
showed signs of ulceration, and both parameters were clin-
ical endpoint criteria that we have previously established.
Draining lymph nodes (DLN) and spleens were removed
from the euthanized mice and subjected to a limiting
dilution assay. Additionally, nitric oxide (NO) release,
arginase activity and cytokine profiles were determined in
both VL and CL experimental models, as described below.
Either in VL and CL, the experiments were repeated once
to ensure reproducible results.
Quantification of parasite burden
Parasite burdens in spleens, livers and in the local DLN
were determined by a limiting dilution assay [52].
Isolation of bone marrow-derived DC (BMDC) and coculture
with splenocytes or DLN cells
Ten days before euthanasia, bone marrow was
harvested from the femurs and tibias of naïve BALB/c
mice (n = 4) and cultured in the presence of 20 ng/mL
murine granulocyte macrophage colony-stimulating
factor (GM-CSF; PeproTech, London, UK), as previ-
ously described [53]. On day 10, nonadherent cells
could be used as DC based on their expression of
CD11c. The BMDC exhibited a myeloid DC phenotype
and were plated at 1 × 106 cells/mL in 6-well plates and
pulsed or not with SLA (50 μg/mL). After 24 h, DC
were collected and used for in vitro stimulation of sple-
nocytes or DLN cells as described below. At 28 and
42 days after L. infantum infection, or 5 weeks after L.
major infection, mice were euthanized, and single-cell
suspensions of the spleens or DLN were prepared,
respectively, and resuspended at a final concentration
of 2 × 106 per mL in complete DMEM medium
supplemented with 10 % heat-inactivated FCS, 2 mM l-
glutamine, 100 U/mL penicillin, and 100 μg/mL
streptomycin in 24-well plates. Cell suspensions and
BMDC, which had been left unstimulated or pulsed
with SLA as described above, were mixed at a ratio of
5:1 and cocultured at 37 °C and 5 % CO2.
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NO assay
The concentration of nitrite, which is a byproduct of NO
production, was measured in the culture supernatant after
96 h using the Griess assay as described [54].
Arginase activity assay
In the VL assays, after removing supernatants to measure
NO release at 96 h, cells were incubated for 30 min in lysis
buffer (0.1 M Tris–HCl, pH 7.5, 300 μM NaCl, 1 μM
PMSF, 1 % Triton X-100). Lysates were then assayed for
intracellular arginase activity as previously described [55].
One unit of enzyme activity was defined as the amount of
enzyme that catalyzes the formation of 1 mmol of urea/
min. In the CL assays, arginase activity at the L. major-in-
fected footpads was determined using 5–10 mL of footpad
homogenate as described elsewhere [27].
Cytokine analysis
Cells were co-cultured for 96 h, and the culture
supernatant was collected and stored at −20 °C. The
production of Ag-specific IL-4 (eBioscience), IL-13
(R&D Systems), IFN-γ and IL-10 (Diaclone) was
determined by ELISA according to the manufacturers’
suggested protocols.
Histopathology
At 42 days after infection with L. infantum, mouse liver
tissues were fixed in fixative solutions and sent to Anapath
(Anatomic Pathology Laboratory, Granada, Spain) for
sectioning, and H&E (hemotoxylin and eosin) staining.
Finally, stained sections were carefully analyzed under the
microscope by Dr. Ana Nieto. We scored granulomas as
previously described [56–59]: immature (developing
granuloma containing infected Kupffer cells), mature
(more developed than immature granulomas), or sterile
(parasite-free granuloma).
Statistical analysis
Statistical analyses were performed using SigmaPlot
version 11.0 (Systat Software, Inc). Data were assessed
for normality and subsequently statistical analyses
were determined by a paired Student t test. Signifi-
cant differences were determined and are designated
with asterisks as follows: *P <0.05, **P <0.01.
Results
HisAK70 protein can be expressed in CHO-K1 cells
The expression of HisAK70 in CHO-K1 cells trans-
fected with pVAX1::HisAK70-asd was detected using a
mouse monoclonal anti-Leishmania A2 antibody and
E-Tag was also detected by monoclonal HRP/ anti-E
Tag Conjugate (Fig. 2).
HisAK70 vaccination induces protection against L.
infantum or L. major infection in mice
We analyzed parasite suppression by comparing each ex-
perimental value with the mean control value. As ex-
pected, empty plasmid (pVAX-asd) immunization was
ineffective in mice, as parasite burdens at various times
p.i. were similar to control values, both in the VL and
CL experimental models. In the VL experimental model,
HisAK70 vaccinated mice had significantly lower para-
site burdens (P < 0.05). Thus, a 30 % reduction in splenic
parasite burden and a 59 % reduction in hepatic parasite
burden were achieved in HisAK70 immunized mice after
28 days of infection with L. infantum. Later, a 40 % re-
duction in splenic parasite burden and a 62 % reduction
in hepatic parasite burden were achieved in those
HisAK70 immunized mice at 42 days p.i.. Finally, after
91 days p.i. a 52 % reduction in parasite burden in spleen
and a 100 % reduction in hepatic parasite load were
achieved in HisAK70 vaccinated mice (Fig. 3a, P < 0.05).
In the CL experimental model, other groups of mice
were infected with L. major parasites in the footpad, and
the time course of swelling at the site of infection was
evaluated. Figure 3b shows that control groups of mice
succumbed to progressive disease. In contrast, vacci-
nated mice with HisAK70 did not show lesions at the
A
B
Fig. 2 Expression of HisAK70 in CHO-K1 cells after transfection. a-b
HisAK70 protein expression was detected from CHO-K1 transfected
cells using specific anti-A2 and anti-E Tag antibodies. Lane 1, total
protein extract from empty vector-transfected cells (pVAX1-asd); lane
2, cells transfected with pVAX1::HISAK70-asd; and lane 3, extract from
non-transfected CHO-K1 cells. Proteins were separated on a 10 %
SDS-PAGE gel. The positions of molecular mass markers are indicated
on the right. HisAK70 (152 kDa) and the control protein loading, β-
Tubulin (52 kDa), are highlighted by arrows, on the left. Data of
one representative out of three independents are given. Relevant
portions of each blot are shown
Domínguez-Bernal et al. Parasites & Vectors  (2015) 8:629 Page 5 of 10
footpad or, in some cases, they had significantly smaller
footpad lesions up to 5 weeks after infection with L.
major, with no signs of ulcer development. Moreover,
the numbers of parasites in popliteal-DLN were signifi-
cantly lower in mice immunized with HisAK70 than
those in control mice (Fig. 3c, P < 0.05), resulting in a
50 % suppression of parasite numbers. Interestingly,
these vaccinated mice did not show the parasite viscera-
lization observed in the control mice (Fig. 3c), resulting
in 100 % inhibition of parasite numbers in the spleen.
HisAK70 vaccination enhances pro-inflammatory/ anti-
inflammatory cytokine secretion ratios after experimental
infection with L. infantum or L. major
The antileishmanial cellular immune responses after in-
fections were evaluated by measuring the production of
both IFN-γ and the anti-inflammatory cytokines (IL-10
and IL-4). Our data showed that control groups of in-
fected mice did not enhance the IFN-γ/ IL-10 (Table 1)
or IFN-γ/ IL-4 (Table 2) ratios in response to SLA-DC
pulsed stimulation, as opposed to what was found in the
L. infantum or L. major- infected mice previously vacci-
nated with HisAK70. Additionally, we found IL-13 levels
at day 42 p.i. to be significantly greater (P < 0.05) in
HisaK70 vaccinated mice compared with levels in L.
infantum infected control mice (Table 1).
HisAK70 DNA vaccination was successful in BALB/c mice
and granulomas completed the maturation stage
It is well established that in human, canine and various
experimental murine (BALB/c and C57BL/6) models of
VL, host resistance is strongly associated with efficient
granuloma development in the liver [58]. Immature
granulomas fail to control infection, but these types of
granulomas decrease in number during the course of L.
infantum infection in BALB/c mice, developing mature
and sterile granulomas to eradicate intracellular para-
sites. Thus, hepatic granulomatous inflammation re-
solves by 8 weeks p.i., with the majority of parasites
cleared [58–60]. As we mentioned before, HisAK70 was
successful in vaccinated mice, resulting in 62 % inhib-
ition of parasite numbers in the liver at day 42 p.i. To
better characterize the ability of HisAK70 vaccine to an-
ticipate antileishmanial protective response, we assessed
granuloma maturation in the livers from L. infantum in-
fected mice. Our results showed that in the control




Fig. 3 HisAK70 vaccination induces protection against L. infantum or
L. major challenges in mice. a Parasite burden was assessed in the
spleen and liver at days 28, 42 and 91 after L. infantum infection by
limiting the dilution assay. b Course of L. major infection in mice.
The mean diameter of induration (± S.D) in the footpad at various
times after infection. c Mean number of parasites per popliteal DLN
and spleen (± S.D) at 5 weeks after L. major infection. Data are
presented as the mean ± S.D. (n = 5). P.N.D., parasites not detected.
Asterisks indicate P < 0.05 with respect to control mice
Table 1 The arginine metabolism and cytokine production in
mice infected with L. infantum at 42 days after infection
Groups of
mice
μM mU Ratio pg/ml
Nitrites Arginase activity IFN-γ/IL-10 IL-13
PBS 8 ± 3 32 ± 5 3,0 218 ± 46
Empty vector 9 ± 4 23 ± 2 2,6 234 ± 38
HisAK70 21 ± 3 (*) 8 ± 3 (*) 7,5 (*) 396 ± 50 (*)
Data are presented as the mean ± S.D. (n = 5). Asterisks indicate P < 0.05 with
respect to control mice
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(Fig. 4a–b) although some sterile granulomas were also
evident. However, the percentage of sterile granulomas
observed in HisK70 vaccinated mice at day 42 p.i. in-
creased by approximately 400 % compared with control
mice (Fig. 4c). A closer histological examination was per-
formed at 91 days p.i (13 weeks) in our laboratory in a
separate experiment and revealed that although the
histological profile was similar in L. infantum infected
mice, control mice were represented by medium and
large-size sterile granulomas, whereas HisaK70 vacci-
nated mice showed sterile granulomas that were
significantly smaller in size (Table 3) and had a different
cellular composition, characterized by a low amount of
Kupffer cells compared to control mice. This evidence
would suggest that cells moved out of the granuloma,
gradually returning the liver to its pre-infection state in
vaccinated mice.
Effects of HisAK70 vaccination in the arginine metabolism
of phagocytic cells during infection in the VL and CL
murine models
Because it has been reported that Leishmania interacts
with the host cell metabolism via arginase or NO syn-
thase [61], we investigated changes in both enzymatic
activities during infection with L. infantum (Table 1) or
L. major (Table 2). As expected, the upregulation of the
arginase pathway restricted arginine accessibility of NO
synthesis and resulted in low nitrite levels in the control
groups of infected mice. Interestingly, HisAK70 vaccin-
ation enhanced the ability of L. infantum or L. major-
infected mice to produce NO in response to SLA-DC
pulsed stimulation. Additionally, compared to the
Table 2 The arginine metabolism and cytokine production in




Nitrites Arginase activity IFN-γ/IL-4
PBS 10 ± 5 4121 ± 813 2,3
Empty vector 11 ± 4 3130 ± 604 3,1
HisAK70 18 ± 2 (*) 601 ± 250 (*) 5,1 (*)
Data are presented as the mean ± S.D. (n = 5). Asterisks indicate P < 0.05 with




Fig. 4 HisAK70 vaccinated mice develop efficient sterile granulomas. Percentage of hepatic granuloma maturation and representative granulomas
from H&E stained liver sections at day 42 p.i. in (a) PBS, (b) empty vector and (c) HisAK70 vaccinated mice. Control mice show high amount of
immature granulomas, whereas HisaK70 vaccinated mice show well-developed mature and sterile granulomas. Images were acquired at the
indicated magnifications and arrows indicate the presence of amastigotes in the granulomas. All data are presented as the representative
mean from each experimental group of mice. Asterisks indicate P < 0.01 with respect to control mice. IM, immature granuloma; M, mature
granuloma; Sterile, parasite-free granuloma
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control groups of mice, HisAK70 vaccinated mice dem-
onstrated dramatically decreased arginase activity at
various times after respective infections.
Discussion
The main goal of the study was to evaluate whether
HisAK70, administered as a DNA vaccine, could induce
protective immune response against VL and CL. Thus,
we employ the well-characterized BALB/c models of L.
infantum and L. major infection. Quantification of para-
site burden in different tissues represents the main tool
for the analysis of immune responses to experimental
leishmaniosis [51]. However, we need to have a clear un-
derstanding about which other remarkable markers are
associated with host immune protection against leishma-
niosis. In this context, previous studies described the
methods used to evaluate L. infantum and L. major in-
fections in mice with regard to the formation of mature
granulomas, that provide the microenvironment for
intracellular parasite killing in the liver [56, 58–60, 62],
and progression of cutaneous lesions at the site of para-
site inoculation [63], respectively. In our study, these
methods have also been used to evaluate HisAK70 DNA
vaccination efficiency.
One of the main safety concerns in the field of DNA
vaccine technology, is the use of antibiotic resistance
genes present in conventional plasmids and which may
have undesirable side-effects. Thus, we followed an alter-
native strategy based on the use of antibiotic-free host-
plasmid balanced lethal systems [46] to select and main-
tain the recombinant plasmid pVAX1::HisAK70-asd. A
major finding of the present study is that this HisAK70
vaccine strategy confers protection against these two
Leishmania species. Such a finding is particularly rele-
vant in the field of control NTD because L. infantum
and L. major species live in diverse regions on the
planet, causing very different forms of disease (visceral
and cutaneous forms). Although these two species have
distinct geographical distributions and are transmitted
by different vector species to different mammalian reser-
voir hosts, there are some evidences of positive gene
flow between L. infantum and L. major. These hybrid
strains were isolated from both the sand fly vector [64]
and immunocompromised patients [65].
Our results suggested that HisAK70 enhances antil-
eishmanial immunity at various stages. Immunization
with HisAK70 noticeably reduced footpad lesions and
parasite burdens relative to infected control mice. It is
well known that anti-Leishmania immunity is most ef-
fectively achieved and maintained by the existence of
persistence parasites. For that reason, an efficient vac-
cine may simply require strengthened immunity against
the development of disease rather than provide sterile
protection [13, 66]. The induction of cross-protection
may be due to diverse components present in HisAK70
vaccine containing epitopes with broad species specifi-
city. Overall, the effectiveness of the HisAK70 vaccine is
based on the ability of immunized mice to achieve the
control of key factors, such as the ratios iNOS/Arginase
activity, IFN-γ /IL-10 or IL-4; a common property previ-
ously described in DNA vaccines [22, 27, 67]. Our find-
ings that the anti-L. infantum response in HisAK70
vaccinated mice developed a high percentage of mature
and sterile granulomas, and was accompanied by signifi-
cant levels of IL-13 at day 42 p.i. support the notion that
this cytokine plays a crucial role in ensuring efficient
hepatic granuloma maturation to control parasite load
during VL [49, 56]. It should be noted that the control
of L. infantum infection in HisAK70 vaccinated mice
has been confirmed in our laboratory after 91 days p.i.
when hepatic parasite burden was fully resolved in these
mice, whereas levels of parasites were maintained in
control mice. At this point, control mice maintained
high chronic parasite burdens in spleen. In contrast,
HisAK70 vaccine contributed to a significant reduction
in the number of parasites in this tissue. These data indi-
cated that although the lack of parasite clearance in the
spleen, HisAK70 immunization is essential to protect
the host against parasite growth and responsible for
parasite control in this organ during late stages of infec-
tion with L. infantum.
Conclusions
We conclude that, despite the main differences in the
mechanisms of pathogenesis between these various
Leishmania species, our data confirm previous evidence
that a vaccine against several Leishmania species is feas-
ible [67–69] thus HisAK70 may be considered a poten-
tial antileishmanial agent. However, improved strategies
for the development of HisAK70-based vaccination and
immunotherapy have yet to be further explored. In the
light of recent studies indicating that a DC-based vac-
cine in combination with DNA improved the immuno-
genicity of the DNA vaccine in mice [70], we decided to
address the role of HisAK70 in this context. Thus, heter-
ologous prime-boost strategies (HisAK70 pulsed-DC
prime-HisAK70-DNA boost and HisAK70-DNA prime-
HisAK70 pulsed-DC boost) are being extensively tested
Table 3 Percentage of various types of hepatic sterile
granulomas in mice infected with L. infantum at 42 days after
infection
Groups of mice Small Medium Large
PBS 19 ± 11 51 ± 14 38 ± 16
Empty vector 21 ± 14 45 ± 10 34 ± 10
HisAK70 92 ± 12 (*) 8 ± 6 (*) ND
Data are presented as the mean ± S.D. (n = 5). Asterisks indicate P < 0.05 with
respect to control mice. N.D not detected
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in our laboratory in order to determine whether similar
strategies can be used to increase vaccine effectiveness.
We hypothesize that these approaches, which combine
HisAK70 immunization regimens, may represent prom-
ising alternatives to induce specific CD4+ and CD8+ T
cell responses, and ensuring long-term immunity against
leishmaniosis. Future development of these studies to
other models (canine) could further demonstrate the po-
tential of HisAK70 vaccine strategy and thereby take an-
other step toward achieving the global control of the
leishmanioses.
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